SCHEMBL3607808

SCHEMBL3607808

COc1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.72
AURKA O14965 1/20 0.52
SYK P43405 7/20 0.50
DYRK1A Q13627 1/20 0.48
DYRK1B Q9Y463 1/20 0.48
RAF1 P04049 1/20 0.48
BRAF P15056 1/20 0.48
KDR P35968 1/20 0.48
PLK1 P53350 1/20 0.48
CCNA2 P20248 1/20 0.47
CDK2 P24941 1/20 0.47
CDK5 Q00535 1/20 0.47
CDK5R1 Q15078 1/20 0.47
EGFR P00533 1/20 0.47
STK10 O94804 1/20 0.46
GSK3B P49841 1/20 0.46
SLK Q9H2G2 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46
USP2 O75604 1/20 0.45
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3602388 0.84 APP (1.00) APPSYKRAF1BRAF
SCHEMBL3581486 0.83 APP (0.63) APPSYKCYP3A4MEN1KMT2A
SCHEMBL3600524 0.80 APP (0.62) APPAURKASYK
SCHEMBL3583812 0.80 SYK (0.61) APPAURKASYKKDRCCNA2
SCHEMBL1735275 0.80 RAF1 (0.59) APPAURKASYKDYRK1ADYRK1B
SCHEMBL3589836 0.80 APP (0.76) APPAURKASYKKDRPLK1
SCHEMBL3594431 0.79 APP (0.61) APPSYKCCNA2CDK2MEN1
SCHEMBL3593855 0.78 APP (0.60) APPSYKKDRPLK1
SCHEMBL3608443 0.77 APP (0.58) APPSYKEGFRKMT2A
SCHEMBL4609188 0.76 SMN1; SMN2 (0.58) KDRUSP2CYP3A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130059871-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES HORWELL DAVID CHRISTOPHER (GB) 2013-03-07 US disclosed
US-20130059871-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES HORWELL DAVID CHRISTOPHER (GB) 2013-03-07 US disclosed
US-20130059871-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES HORWELL DAVID CHRISTOPHER (GB) 2013-03-07 US disclosed
US-20100063077-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-03-11 US disclosed
US-20100063077-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-03-11 US disclosed
US-20100063077-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-03-11 US disclosed
EP-2010502-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES Senexis Limited (GB) 2009-01-07 EP disclosed
WO-2007125351-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063077-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES TYMP, APP, HTT APP 2/4885AURKA 3836/4885SYK 3311/4885
US-20130059871-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES TYMP, APP, HTT APP 2/4885AURKA 3836/4885SYK 3311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.